Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
The pharmaceutical and biotech sectors have seen a flurry of executive movement this month, with leadership changes spanning ...
Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
This illustration shows targeted alpha therapy, in which actinium-225 is linked to a targeting molecule that binds to a ...
NEW YORK – Novartis' key patent on its radioligand therapy Lutathera (lutetium Lu 177 dotatate) isn't set to expire until 2038, but radiopharmaceutical company Lantheus is already preparing to ...
Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected ...
(UroToday.com) The 2026 European Association of Urology (EAU) Annual Meeting held in London, U.K., was host to the Hormone sensitive metastatic prostate cancer: Thematic Session. Dr. Declan Murphy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results